{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T18:04:40Z","timestamp":1795025080664,"version":"4.10.2"},"reference-count":43,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T00:00:00Z","timestamp":1629763200000},"content-version":"unspecified","delay-in-days":23,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"W.L. GORE & Associates"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Gastroenterol"],"accepted":{"date-parts":[[2021,7,18]]},"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Transjugular intrahepatic portosystemic stent shunt (TIPSS) is clinically effective in variceal bleeding and refractory ascites; however, the cost-effectiveness of TIPSS has yet to be evaluated in the UK. This study aimed to establish the cost-effectiveness of (i) pre-emptive TIPSS versus endoscopic band ligation (EBL) in populations with variceal bleeding and (ii) TIPSS versus large volume paracentesis (LVP) in refractory ascites.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A cost-utility analysis was conducted with the perspective including healthcare costs and quality-adjusted life years (QALYs). A Markov model was constructed with a 2-year time horizon, health states for mortality and survival and probabilities for the development of variceal bleeding, ascites and hepatic encephalopathy. A survival analysis was conducted to extrapolate 12-month to 24-month mortality for the refractory ascites indication. Uncertainty was analysed in deterministic and probabilistic sensitivity analyses.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>TIPSS was cost-effective (dominant) and cost saving for both indications. For variceal bleeding, pre-emptive TIPSS resulted in 0.209 additional QALYs, and saved \u00a3600 per patient compared with EBL. TIPSS had a very high probability of being cost-effective (95%) but was not cost saving in scenario analyses driven by rates of variceal rebleeding. For refractory ascites, TIPSS resulted in 0.526 additional QALYs and saved \u00a317\u2009983 per patient and had a 100% probability of being cost-effective and cost saving when compared with LVP.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>TIPSS is a cost-effective intervention for variceal bleeding and refractory ascites. TIPSS is highly cost-saving for refractory ascites. Robust randomised trial data are required to confirm whether pre-emptive TIPSS is cost saving for variceal bleeding.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjgast-2021-000641","type":"journal-article","created":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T13:02:20Z","timestamp":1629810140000},"page":"e000641","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Economic evaluation of covered stents for transjugular intrahepatic portosystemic stent shunt in patients with variceal bleeding and refractory ascites secondary to cirrhosis"],"prefix":"10.1136","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7517-5233","authenticated-orcid":false,"given":"Richard","family":"Mattock","sequence":"first","affiliation":[{"name":"York Health Economics Consortium, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhiraj","family":"Tripathi","sequence":"additional","affiliation":[{"name":"Liver Unit, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"O'Neill","sequence":"additional","affiliation":[{"name":"Associate, W.L. Gore and Associates, Livingston, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce","family":"Craig","sequence":"additional","affiliation":[{"name":"York Health Economics Consortium, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Tanner","sequence":"additional","affiliation":[{"name":"Associate, W.L. Gore and Associates, Livingston, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Patch","sequence":"additional","affiliation":[{"name":"Hepatology and Liver Transplantation, Royal Free London NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guruprasad","family":"Aithal","sequence":"additional","affiliation":[{"name":"Faculty of Medicine & Health Sciences, The University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,8,24]]},"reference":[{"key":"2025073013145596000_8.1.e000641.1","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S2468-1253(19)30349-8","article-title":"The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017","volume":"5","author":"","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025073013145596000_8.1.e000641.2","unstructured":"Dorrell S . Government\u2019s alcohol strategy: third report of session 2012-13, Vol. 1: Report. together with formal minutes oral and written evidence: The Stationery Office; 2012."},{"key":"2025073013145596000_8.1.e000641.3","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000062","article-title":"Increasing economic burden in hospitalized patients with cirrhosis: analysis of a national database","volume":"10","author":"Desai","year":"2019","journal-title":"Clin Transl Gastroenterol"},{"key":"2025073013145596000_8.1.e000641.4","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S2468-1253(17)30362-X","article-title":"Cirrhosis with ascites in the last year of life: a nationwide analysis of factors shaping costs, health-care use, and place of death in England","volume":"3","author":"Hudson","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025073013145596000_8.1.e000641.5","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23500"},{"key":"2025073013145596000_8.1.e000641.6","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ejim.2019.09.004","article-title":"Health-Related quality of life in patients with compensated and decompensated liver cirrhosis","volume":"70","author":"Labenz","year":"2019","journal-title":"Eur J Intern Med"},{"key":"2025073013145596000_8.1.e000641.7","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1055\/s-0034-1382794","article-title":"The history and future of transjugular intrahepatic portosystemic shunt: food for thought","volume":"31","author":"Saad","year":"2014","journal-title":"Semin Intervent Radiol"},{"key":"2025073013145596000_8.1.e000641.8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2007.01522.x"},{"key":"2025073013145596000_8.1.e000641.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.01.015"},{"key":"2025073013145596000_8.1.e000641.10","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1056\/NEJMoa0910102","article-title":"Early use of TIPS in patients with cirrhosis and variceal bleeding","volume":"362","author":"Garc\u00eda-Pag\u00e1n","year":"2010","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025073013145596000_8.1.e000641.11","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.09.016"},{"key":"2025073013145596000_8.1.e000641.12","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-320221"},{"key":"2025073013145596000_8.1.e000641.13","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-321790"},{"key":"2025073013145596000_8.1.e000641.14","unstructured":"NICE . Cirrhosis in over 16s: assessment and management. NICE guideline [NG50]. London National Institute for Health and Care Excellence (NICE); 2016."},{"key":"2025073013145596000_8.1.e000641.15","unstructured":"NICE . Acute upper gastrointestinal bleeding in over 16s: management. Clinical guideline [CG141]. London National Institute for Health and Care Excellence (NICE); 2016."},{"key":"2025073013145596000_8.1.e000641.16","unstructured":"NICE . Developing NICE guidelines: the manual. Process and methods [PMG20]: National Institute for Health and Care Excellence (NICE) 2018."},{"key":"2025073013145596000_8.1.e000641.17","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-1018-z"},{"key":"2025073013145596000_8.1.e000641.18","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-BASL.68"},{"key":"2025073013145596000_8.1.e000641.19","doi-asserted-by":"crossref","first-page":"346","DOI":"10.5152\/dir.2019.18416","article-title":"Long-Term follow-up of transjugular intrahepatic portosystemic shunt (TIPS) with stent-graft","volume":"25","author":"Perell\u00f3","year":"2019","journal-title":"Diagn Interv Radiol"},{"key":"2025073013145596000_8.1.e000641.20","doi-asserted-by":"publisher","DOI":"10.1097\/01.RVI.0000136828.42612.B4"},{"key":"2025073013145596000_8.1.e000641.21","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.cgh.2018.03.027","article-title":"Cost effectiveness of early insertion of transjugular intrahepatic portosystemic shunts for recurrent ascites","volume":"16","author":"Shen","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025073013145596000_8.1.e000641.22","unstructured":"National schedule of reference costs 2017\/18, 2018. Available: https:\/\/improvement.nhs.uk\/resources\/national-cost-collection\/"},{"key":"2025073013145596000_8.1.e000641.23","unstructured":"Joint Formulary Committee . BNF 77 (British National formulary) March 2019. Pharmaceutical Press, 2019."},{"key":"2025073013145596000_8.1.e000641.24","unstructured":"PSSRU . Unit costs of health & social care, 2019. Available: https:\/\/www.pssru.ac.uk\/project-pages\/unit-costs\/unit-costs-2019\/"},{"key":"2025073013145596000_8.1.e000641.25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2001.03537.x"},{"key":"2025073013145596000_8.1.e000641.26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2011.02598.x"},{"key":"2025073013145596000_8.1.e000641.27","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1185\/030079907X199736","article-title":"An economic evaluation of vasoactive agents used in the United Kingdom for acute bleeding oesophageal varices in patients with liver cirrhosis","volume":"23","author":"Wechowski","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"2025073013145596000_8.1.e000641.28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2005.08101.x"},{"key":"2025073013145596000_8.1.e000641.29","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/apt.15797","article-title":"Randomised clinical trial: standard of care versus early-transjugular intrahepatic porto-systemic shunt (TIPSS) in patients with cirrhosis and oesophageal variceal bleeding","volume":"52","author":"Dunne","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"2025073013145596000_8.1.e000641.30","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"key":"2025073013145596000_8.1.e000641.31","doi-asserted-by":"publisher","DOI":"10.1136\/flgastro-2012-100283"},{"key":"2025073013145596000_8.1.e000641.32","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.jvir.2018.08.019","article-title":"Cost-Effectiveness of transjugular intrahepatic portosystemic shunt versus large-volume paracentesis in refractory ascites: results of a Markov model incorporating individual patient-level meta-analysis and nationally representative cost data","volume":"29","author":"Kwan","year":"2018","journal-title":"J Vasc Interv Radiol"},{"key":"2025073013145596000_8.1.e000641.33","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1053\/j.gastro.2015.01.032","article-title":"Decreasing mortality among patients hospitalized with cirrhosis in the United States from 2002 through 2010","volume":"148","author":"Schmidt","year":"2015","journal-title":"Gastroenterology"},{"key":"2025073013145596000_8.1.e000641.34","doi-asserted-by":"crossref","unstructured":"Khan F , Tripathi D . Early TIPSS in patients with cirrhosis and acute variceal bleeding\u2014the plot thickens! Wiley Online Library, 2020.","DOI":"10.1111\/apt.15904"},{"key":"2025073013145596000_8.1.e000641.35","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2019-000290"},{"key":"2025073013145596000_8.1.e000641.36","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30840-7"},{"key":"2025073013145596000_8.1.e000641.37","unstructured":"ClinicalTrials.gov . Identifier NCT03083925, Viatorr CX case-control study for complications of portal hypertension (VIATORR-CX). Bethesda (MD) National Library of Medicine(US); 2019."},{"key":"2025073013145596000_8.1.e000641.38","unstructured":"ClinicalTrials.gov . Identifier NCT04315571, comparing ascites relief in two standard treatments: large volume paracentesis vs. early tips using Viatorr controlled expansion stents. Bethesda (MD) National Library of Medicine(US); 2019."},{"key":"2025073013145596000_8.1.e000641.39","doi-asserted-by":"crossref","first-page":"100264","DOI":"10.1016\/j.jhepr.2021.100264","article-title":"Controlled underdilation using novel VIATORR\u00ae controlled expansion stents improves survival after transjugular intrahepatic portosystemic shunt implantation","volume":"3","author":"Praktiknjo","year":"2021","journal-title":"JHEP Rep"},{"key":"2025073013145596000_8.1.e000641.40","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S2468-1253(19)30090-1","article-title":"Early TIPS with covered stents versus standard treatment for acute variceal bleeding in patients with advanced cirrhosis: a randomised controlled trial","volume":"4","author":"Lv","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025073013145596000_8.1.e000641.41","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.3748\/wjg.v20.i10.2704","article-title":"TIPS improves liver transplantation-free survival in cirrhotic patients with refractory ascites: an updated meta-analysis","volume":"20","author":"Bai","year":"2014","journal-title":"World J Gastroenterol"},{"key":"2025073013145596000_8.1.e000641.42","unstructured":"Mullan D , Kibriya N , Jacob A . Draining malignant ascites at home with tunnelled catheters: complications and costs 2015."},{"key":"2025073013145596000_8.1.e000641.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhin.2017.03.004"}],"container-title":["BMJ Open Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgast-2021-000641","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T20:15:07Z","timestamp":1753906507000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopengastro.bmj.com\/lookup\/doi\/10.1136\/bmjgast-2021-000641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,8,24]]},"published-print":{"date-parts":[[2021,8]]}},"alternative-id":["10.1136\/bmjgast-2021-000641"],"URL":"https:\/\/doi.org\/10.1136\/bmjgast-2021-000641","relation":{},"ISSN":["2054-4774"],"issn-type":[{"value":"2054-4774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8]]}}}